Premium
TafluprostTM in clinical practice
Author(s) -
HOMMER A
Publication year - 2010
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2010.468.x
Subject(s) - latanoprost , tolerability , medicine , glaucoma , benzalkonium chloride , intraocular pressure , ophthalmology , prostaglandin analogue , travoprost , adverse effect , pathology
Lowering intraocular pressure is currently the only proven approach to preserve visual function in glaucoma. Hereby medical therapy is the initial treatment option. According to the guidelines of the European Glaucoma Society monotherapy is the first step in medical therapy. Prostaglandin analogues (PG) are approved for first line therapy for several years and they are the most frequently used IOP lowering agents now, because of their strong IOP lowering effect and once daily application. All PG that have been on the market are containing Benzalkonium chloride (BAK) as preservatives. These preservatives may cause tolerability problems and inflammation. Dry eyes and ocular surface disorders (OSD) have been limiting the use of PG with BAK. The introduction of Tafluprost without BAK is a significant addition in our medical options for glaucoma treatment. In clinical use we can consider Tafluprost sine as a useful option in patients with dry eye, ocular surface disorder, allergy to BAK or intolerability. The IOP lowering effect is comparable to the most frequently used PG Latanoprost. The application is once daily as well. Because of the high rate of dry eye patients and OSD patients Tafluprost sine is a very useful option. If these patients need more than one medication the combination of Cosopt sine and Tafluprost sine is an option of three IOP lowering molecules with three drops a day in total but unpreserved.